Merck treads water in Q4 as Keytruda helps offset Remicade suffering

Tracy Staton

& Co. took a one-two punch in the fourth quarter. Revenue from two top-selling franchises–Januvia and –slid, dragging overall sales below analyst estimates at $ 10.2 billion. One bright spot? A lower tax rate managed to boost Merck's earnings above analyst estimates at 93 cents per share.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS